RxDoctor Payments Data

Nour Abuhadra

Medical Oncology · New York, NYNPI 1598146227

Payments from drug & device makers

$574,595in general payments, 2019–2025

Across 7 payments — averaging $82,085 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$504K
  • Genentech, Inc.$68K
  • Gilead$3K
  • Amgen$25

What the payments were for

  • Consulting fees$2,70099%
  • Food & beverage$251%

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$503,638
Genentech, Inc.4$68,232
Gilead1$2,700
Amgen1$25

How this compares

$574,595 in reported general payments places this provider in the 65th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$51,635
Medicare patients
95
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib15$204,372
TukysaTucatinib15$192,244
KisqaliRibociclib Succinate11$155,942
Letrozole103$2,340
Anastrozole29$619
Tamoxifen Citrate13$202
Dexamethasone12$190

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →